4.6 Article

Definition of the Nature and Hapten Threshold of the β-Lactam Antigen Required for T Cell Activation In Vitro and in Patients

期刊

JOURNAL OF IMMUNOLOGY
卷 198, 期 11, 页码 4217-4227

出版社

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1700209

关键词

-

资金

  1. Cystic Fibrosis Trust [PJ533]
  2. Centre for Drug Safety Science - Medical Research Council [G0700654]
  3. Medical Research Council [MR/L006758/1, G0700654] Funding Source: researchfish
  4. MRC [G0700654, MR/L006758/1] Funding Source: UKRI

向作者/读者索取更多资源

Covalent modification of protein by drugs may disrupt self-tolerance, leading to lymphocyte activation. Until now, determination of the threshold required for this process has not been possible. Therefore, we performed quantitative mass spectrometric analyses to define the epitopes formed in tolerant and hypersensitive patients taking the beta-lactam antibiotic piperacillin and the threshold required for T cell activation. A hydrolyzed piperacillin hapten was detected on four lysine residues of human serum albumin (HSA) isolated from tolerant patients. The level of modified Lys(541) ranged from 2.6 to 4.8%. Analysis of plasma from hypersensitive patients revealed the same pattern and levels of modification 1-10 d after the commencement of therapy. Piperacillin-responsive skin-homing CD4(+) clones expressing an array of V beta receptors were activated in a dose-, time-, and processing-dependent manner; analysis of incubation medium revealed that 2.6% of Lys(541) in HSA was modified when T cells were activated. Piperacillin-HSA conjugates that had levels and epitopes identical to those detected in patients were shown to selectively stimulate additional CD4(+) clones, which expressed a more restricted Vb repertoire. To conclude, the levels of piperacillin-HSA modification that activated T cells are equivalent to the ones formed in hypersensitive and tolerant patients, which indicates that threshold levels of drug Ag are formed in all patients. Thus, the propensity to develop hypersensitivity is dependent on other factors, such as the presence of T cells within an individual's repertoire that can be activated with the b-lactam hapten and/or an imbalance in immune regulation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Respiratory System

Ways of coping and survival in Cystic Fibrosis: a 20-year longitudinal study

Janice Abbott, Margaret A. Hurley, Helen Chadwick, Daniel Peckham

Summary: This study found that optimistic coping has a positive impact on the survival of cystic fibrosis patients, while other coping strategies do not show significant effects. This finding is important for clinical interventions and improving quality of life and longevity.

JOURNAL OF CYSTIC FIBROSIS (2023)

Article Respiratory System

The risk of colorectal cancer in individuals with mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene: An English population-based study

Rebecca J. Birch, Daniel Peckham, Henry M. Wood, Philip Quirke, Rob Konstant-Hambling, Keith Brownlee, Rebecca Cosgriff, Nicholas Burr, Amy Downing

Summary: It has been found that individuals with Cystic Fibrosis (CF) have a higher risk of developing colorectal cancer (CRC), and carriers of cystic fibrosis transmembrane conductance regulator (CFTR) mutations may also face an increased risk. With the increasing life expectancy of CF patients, more individuals are at risk of developing CRC.

JOURNAL OF CYSTIC FIBROSIS (2023)

Review Gastroenterology & Hepatology

Cystic Fibrosis-Related Gut Dysbiosis: A Systematic Review

L. R. Caley, H. White, M. C. de Goffau, R. A. Floto, J. Parkhill, B. Marsland, D. G. Peckham

Summary: Gut dysbiosis is evident in individuals with cystic fibrosis (CF), characterized by reduced diversity and taxonomic changes. The relationship between gut dysbiosis and systemic and lung inflammation is limited. The causes of gut dysbiosis are multifactorial and the impact of CFTR modulators on the gut microbiota is still unclear.

DIGESTIVE DISEASES AND SCIENCES (2023)

Article Respiratory System

Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis

L. R. Caley, C. Zagoya, F. Duckstein, H. White, D. Shimmin, A. M. Jones, J. Barrett, J. L. Whitehouse, R. A. Floto, J. G. Mainz, D. G. Peckham

Summary: This study compared gastrointestinal symptoms in patients with cystic fibrosis and cystic fibrosis-related diabetes. It found that individuals with cystic fibrosis-related diabetes have a higher burden of gastrointestinal symptoms, particularly bloating and nausea.

JOURNAL OF CYSTIC FIBROSIS (2023)

Review Critical Care Medicine

Impact of Digital Technologies on Clinical Care for Adults with Cystic Fibrosis

Daniel Peckham, Giulia Spoletini

Summary: The COVID-19 pandemic has accelerated the use of digital technologies in managing chronic diseases such as cystic fibrosis. Even with eased restrictions, these technologies like video and telephone consultations and remote monitoring are likely to remain crucial in the future of CF healthcare, thanks to improved clinical stability from effective modulator therapy.

SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Article Medicine, General & Internal

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

Felicity Liew, Shubha Talwar, Andy Cross, Brian J. Willett, Sam Scott, Nicola Logan, Matthew K. Siggins, Dawid Swieboda, Jasmin K. Sidhu, Claudia Efstathiou, Shona C. Moore, Chris Davis, Noura Mohamed, Jose Nunag, Clara King, A. A. Roger Thompson, Sarah L. Rowland-Jones, Annemarie B. Docherty, James D. Chalmers, Ling-Pei Ho, Alexander Horsley, Betty Raman, Krisnah Poinasamy, Michael Marks, Onn Min Kon, Luke Howard, Daniel G. Wootton, Susanna Dunachie, Jennifer K. Quint, Rachael A. Evans, Louise V. Wain, Sara Fontanella, Thushan I. de Silva, Antonia Ho, Ewen Harrison, J. Kenneth Baillie, Malcolm G. Semple, Christopher Brightling, Ryan S. Thwaites, Lance Turtle, Peter J. M. Openshaw

Summary: This study examined the nasal and plasma antibody responses in COVID-19 hospitalized patients one year after discharge and vaccination. The findings showed sustained elevated antibody responses in both nasal and plasma samples for at least 12 months, but the nasal antibody response was minimally influenced by vaccination. These findings highlight the importance of developing vaccines that enhance nasal immunity.

EBIOMEDICINE (2023)

Review Respiratory System

Physical activity promotion interventions in chronic airways disease: a systematic review and meta-analysis

Caroline Reilly, Joe Sails, Antonios Stavropoulos-Kalinoglou, Rebecca J. Birch, Jim McKenna, Ian J. Clifton, Daniel Peckham, Karen M. Birch, Oliver J. Price

Summary: Physical inactivity is common in people with chronic airways disease and is associated with worse clinical outcomes and impaired quality of life. A systematic review and meta-analysis found that interventions promoting step-based physical activity, particularly those incorporating wearable activity monitors, resulted in a significant and clinically meaningful improvement in daily step count in pwCAD.

EUROPEAN RESPIRATORY REVIEW (2023)

Review Respiratory System

Role of inhaled antibiotics in the era of highly effective CFTR modulators

J. Stuart Elborn, Francesco Blasi, Pierre-Regis Burgel, Daniel Peckham

Summary: Recurrent and chronic bacterial infections are common in people with cystic fibrosis (CF). Antibiotics are the mainstay in treatment, but inhaled antibiotics have limited systemic adverse effects. In the past decade, highly effective CFTR modulators have become a new therapy that partially corrects chloride transport, improving lung function. While these modulators have a significant impact, they do not fully resolve chronic lung damage. This article reviews the role of inhaled antibiotics in the era of CFTR modulators.

EUROPEAN RESPIRATORY REVIEW (2023)

Article Allergy

Prevalence of CFTR variants in primary immunodeficiency patients with bronchiectasis is an important modifying cofactor

Dylan Lawless, Hana Lango Allen, James E. D. Thaventhiran, Sarah Goddard, Oliver S. Burren, Evie Robson, N. I. H. R. BioResource Rare Dis Consortium NIHR BioResource Rare Dis Consortium, Daniel Peckham, Kenneth G. C. Smith, Sinisa Savic

Summary: This study analyzed the manifestation of cystic fibrosis (CF), a common genetic disorder, in patients with primary immunodeficiency (PID). The research found that patients carrying specific CFTR gene variants had worse outcome in terms of structural lung disease. Genome sequencing also identified cases of CFTR dysfunction in PID, suggesting the potential of precision medicine in treating traditional Mendelian disorders.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2023)

Article Immunology

Butyrate regulates neutrophil homeostasis and impairs early antimicrobial activity in the lung

Anh Thu Dang, Christina Begka, Celine Pattaroni, Laura R. Caley, R. Andres Floto, Daniel G. Peckham, Benjamin J. Marsland

Summary: Short-chain fatty acids (SCFAs), produced from the microbial fermentation of dietary fiber, have an impact on cell metabolism and anti-inflammatory pathways. However, the administration of butyrate, a type of SCFA, affects neutrophil maturation and function in the bone marrow, resulting in a decreased ability to control bacterial infections in the lungs.

MUCOSAL IMMUNOLOGY (2023)

Correction Pharmacology & Pharmacy

Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score (vol 13, 877118, 2022)

Jochen G. Mainz, Carlos Zagoya, Louise Polte, Lutz Naehrlich, Lenny Sasse, Olaf Eickmeier, Christina Smaczny, Anton Barucha, Lilith Bechinger, Franziska Duckstein, Ludwik Kurzidim, Patience Eschenhagen, Laura Caley, Daniel Peckham, Carsten Schwarz

FRONTIERS IN PHARMACOLOGY (2023)

Article Critical Care Medicine

Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials

Ahmet Z. Uluer, Gordon MacGregor, Pilar Azevedo, Veronica Indihar, Claire Keating, Marcus A. Mall, Edward F. McKone, Bonnie W. Ramsey, Steven M. Rowe, Ronald C. Rubenstein, Jennifer L. Taylor-Cousar, Elizabeth Tullis, Lael M. Yonker, Chenghao Chu, Anna P. Lam, Nitin Nair, Patrick R. Sosnay, Simon Tian, Fredrick Van Goor, Lakshmi Viswanathan, David Waltz, Linda T. Wang, Yingmei Xi, Joanne Billings, Alexander Horsley

Summary: This study demonstrates that once-daily dosing with vanzacaftor-tezacaftor-deutivacaftor is safe and effective in improving lung function and respiratory symptoms in patients with cystic fibrosis, and it enhances CFTR function.

LANCET RESPIRATORY MEDICINE (2023)

Article Critical Care Medicine

Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study

Callum Jackson, Iain Stewart, Tatiana Plekhanova, Peter S. Cunningham, Andrew L. Hazel, Bashar Al-Sheklly, Raminder Aul, Charlotte E. Bolton, Trudie Chalder, James D. Chalmers, Nazia Chaudhuri, Annemarie B. Docherty, Gavin Donaldson, Charlotte L. Edwardson, Omer Elneima, Neil J. Greening, Neil A. Hanley, Victoria C. Harris, Ewen M. Harrison, Ling-Pei Ho, Linzy Houchen-Wolloff, Luke S. Howard, Caroline J. Jolley, Mark G. Jones, Olivia C. Leavy, Keir E. Lewis, Nazir Lone, Michael Marks, Hamish J. C. McAuley, Melitta A. McNarry, Brijesh Patel, Karen Piper-Hanley, Krisnah Poinasamy, Betty Raman, Matthew Richardson, Pilar Rivera-Ortega, Sarah L. Rowland-Jones, Alex Rowlands, Ruth M. Saunders, Janet T. Scott, Marco Sereno, Ajay M. Shah, Aarti Shikotra, Amisha Singapuri, Stefan C. Stanel, Mathew Thorpe, Daniel G. Wootton, Thomas Yates, R. Gisli Jenkins, Sally J. Singh, William D-C Man, Christopher E. Brightling, Louise Wain, Joanna C. Porter, A. A. Roger Thompson, Alex Horsley, Philip L. Molyneaux, Rachael A. Evans, Samuel E. Jones, Martin K. Rutter, John F. Blaikley, PHOSP-COVID Study Collaborative Grp

Summary: This study investigated the prevalence and nature of sleep disturbance after discharge following hospital admission for COVID-19 and found that sleep disturbance is associated with dyspnoea, anxiety, and muscle weakness. Targeting sleep disturbance might be beneficial in treating the post-COVID-19 condition.

LANCET RESPIRATORY MEDICINE (2023)

Article Medicine, General & Internal

Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

Hamish J. C. McAuley, Rachael A. Evans, Charlotte E. Bolton, Christopher E. Brightling, James D. Chalmers, Annemarie B. Docherty, Omer Elneima, Paul L. Greenhaff, Ayushman Gupta, Victoria C. Harris, Ewen M. Harrison, Ling-Pei Ho, Alex Horsley, Linzy Houchen-Wolloff, Caroline J. Jolley, Olivia C. Leavy, Nazir I. Lone, William D. C. Man, Michael Marks, Dhruv Parekh, Krisnah Poinasamy, Jennifer K. Quint, Betty Raman, Matthew Richardson, Ruth M. Saunders, Marco Sereno, Aarti Shikotra, Amisha Singapuri, Sally J. Singh, Michael Steiner, Ai Lyn Tan, Louise Wain, Carly Welch, Julie Whitney, Miles D. Witham, Janet Lord, Neil J. Greening, HOSP-COVID Study Collaborat Grp

Summary: This study recruited COVID-19 survivors in the UK and objectively measured frailty using FFP. The results showed that frailty and pre-frailty are common after hospitalization with COVID-19, and comprehensive assessment and interventions targeting frailty are needed beyond the initial illness.

ECLINICALMEDICINE (2023)

Article Health Care Sciences & Services

Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

Bang Zheng, Giulia Vivaldi, Luke Daines, Olivia C. Leavy, Matthew Richardson, Omer Elneima, Hamish J. C. McAuley, Aarti Shikotra, Amisha Singapuri, Marco Sereno, Ruth M. Saunders, Victoria C. Harris, Linzy Houchen-Wolloff, Neil J. Greening, Paul E. Pfeffer, John R. Hurst, Jeremy S. Brown, Manu Shankar-Hari, Carlos Echevarria, Anthony De Soyza, Ewen M. Harrison, Annemarie B. Docherty, Nazir Lone, Jennifer K. Quint, James D. Chalmers, Ling-Pei Ho, Alex Horsley, Michael Marks, Krishna Poinasamy, Betty Raman, Liam G. Heaney, Louise V. Wain, Rachael A. Evans, Christopher E. Brightling, Adrian Martineau, Aziz Sheikh

Summary: This study investigated the determinants of recovery from dyspnoea in adults with COVID-19 and compared them to non-COVID-19 patients. The results showed that the factors associated with dyspnoea recovery in COVID-19 patients were similar to those in non-COVID-19 patients. These factors included age, gender, obesity status, mental health, cardiovascular disease, and length of hospital admission.

LANCET REGIONAL HEALTH-EUROPE (2023)

暂无数据